triple-negative breast cancer

Biotech

Puma pounces on failed Takeda drug, snapping up cancer prospect

Puma landed a global license for $7 million upfront, plus up to $287.3 million in milestones, and plans to target breast and small cell lung cancer.
Nick Paul Taylor Sep 21, 2022 9:05am

CytomX puts lead ADC on the block after phase 2 data underwhelm

Jul 7, 2022 8:45am

An mRNA therapy might boost response to I-O in breast cancer

Mar 22, 2022 9:10am

Heart arrhythmia drug reduces tumor spread in cancer mouse model

Jan 18, 2022 8:55am

Sanofi inks $270M cancer AI deal with developer Owkin

Nov 18, 2021 1:30am

Targeting tumor-driving RNA proteins in aggressive breast cancer

Jul 2, 2021 11:00am